Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
SPRY
SPRY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SPRY News
Aquestive Therapeutics Receives Complete Response Letter from FDA
Feb 02 2026
Benzinga
ARS Pharmaceuticals Secures Expanded Authorization for EURneffy
Feb 02 2026
NASDAQ.COM
ARS Pharmaceuticals Stock Rises 18.86% Following FDA Update on Rival Aquestive
Jan 09 2026
Benzinga
Aquestive Therapeutics Faces 40% Stock Drop After FDA Identifies Deficiencies in Anaphylm NDA
Jan 09 2026
Benzinga
ARS Pharma's Neffy Approved in China for Allergy Treatment
Jan 02 2026
NASDAQ.COM
ARS Pharma's neffy Approved as First Community Use Epinephrine Product in China
Dec 29 2025
Globenewswire
ARS Pharma's Neffy Approved in China for Allergy Treatment
Dec 29 2025
Newsfilter
ARS Pharmaceuticals to Showcase neffy® at Piper Sandler Healthcare Conference
Nov 26 2025
Globenewswire
ARS Pharma to Showcase Real-World Data on Intranasal Epinephrine at the 2025 ACAAI Annual Scientific Meeting
Nov 03 2025
Newsfilter
ARS Pharma to Showcase Real-World Findings on Intranasal Epinephrine at the 2025 ACAAI Annual Scientific Meeting
Nov 03 2025
Newsfilter
ARS Pharmaceuticals (SPRY) Rises 5.2% Following $250M Term Loan Acquisition to Speed Up Neffy Launch – Is the Bullish Outlook Still Valid?
Oct 04 2025
Yahoo Finance
ARS Pharma Calls on FDA to Postpone Approval of Aquestive's Allergy Treatment
Sep 23 2025
Benzinga
Top Analysts Recommend 3 Stocks to Purchase Now, 9/23/2025
Sep 23 2025
TipRanks
Market Update: Health Care Stocks Gain Ahead of Friday's Opening Bell
Sep 19 2025
Yahoo Finance
Neffy® (epinephrine nasal spray) Receives Approval in Japan as the First and Sole Needle-Free Emergency Treatment for Anaphylaxis
Sep 19 2025
Newsfilter
ARS Pharma Shares Fall 9% Following Lupin's Generic Neffy Application Submission
Aug 29 2025
SeekingAlpha
Show More News
